Blue Chip Stamps v. Manor Drug Stores

Standing to bring private Rule 10b-5 damages actions and the purchaser-seller limitation.

Under an antitrust consent decree, Blue Chip was required to offer shares to retailers that had previously used its trading-stamp service. Manor Drug Stores alleged that the offering materials were misleadingly pessimistic and deterred it from purchasing shares, then brought a Rule 10b-5 damages action despite not buying or selling securities.

The Court adopted the purchaser-seller rule, limiting private Rule 10b-5 damages actions to actual purchasers or sellers of securities.

Justice Rehnquist emphasized administrability, evidentiary reliability, and the risk of vexatious strike suits if disappointed nonpurchasers or nonsellers could sue based on hypothetical transactions. The Court treated the limitation as a way to contain litigation costs in implied securities-fraud actions.

1. How does the rule affect information production, investor reliance, and enforcement costs?
2. What are the likely error costs for lawful market activity and for undetected misconduct?